New Therapies for ARMD 1 Thursday 17 May 14:30 - 16:00 Salle Camille Blanc
A. Loewenstein,
ISRAEL
Patient-reported visual function outcomes over 2 years in the ANCHOR study comparing ranibizumab with verteporfin PDT
Purpose: To examine the effects of ranibizumab on patient-reported visual function, using the NEIVFQ-25 questionnaire, in patients with predominantly classic subfoveal CNV. Setting: Randomized, double-blind, sham-controlled trial over 2 years in a total of 423 patients. Methods: Patients were randomized 1:1:1 to receive monthly ranibizumab 0.3mg (n=140) or 0.5mg (n=143) with sham PDT every 3 months as required, or monthly sham injection plus verteporfin PDT every 3 months as required (n=140). The effects of ranibizumab on patients perceived visual function were assessed using the National Eye Institute Visual Function Questionaire (NEIVFQ-25) at baseline and months 1,2,3,6,9,12,18 and 24. Visual function was assessed by change in mean score from baseline at months 12 and 24 for each of the near-, distance- and vision-related dependency subscales, scored from 0-100, where a positive difference represents improved functioning or reduced dependency. Results: At the end of year 1, patients treated with ranibizumab 0.3mg or 0.5mg showed significant improvements in near activities, distance activities and vision-specific dependency when compared to verteporfin PDT treatment. Two year results from ANCHOR are currently under analysis and will be presented at the meeting. Conclusions: Clinically, improvements in VFQ-25 subscale scores represent greater patient-reported perception of ability to perform daily tasks such as face recognition, social function, reading, and driving. Financial disclosure: Yes
